Abstract | The kallikrein, prostate-specific antigen (PsA), is one of the world's most frequently used disease biomarkers. After almost two decades of research and clinical experience, the diagnostic and monitoring limitations of PsA are beginning to be understood. Most physicians are aware of PsA's low specificity for cancer among older men with benign prostatic conditions; fewer are aware of recent data, which show that a prior negative biopsy or a prior PsA value below the threshold for biopsy might compromise the predictive accuracy of PsA even further. Furthermore, a subtle increase in serum PsA level during early middle age is strongly correlated with clinically important prostate cancer. we review current and past reports on the prostate kallikreins PsA and hK2 in relation to pathology and epidemiology.
Introduction
Human kallikrein-related peptidase 3-commonly referred to as prostate-specific antigen (PSA)-and kallikrein-related peptidase 2 (hK2) are abundantly produced by and released from the prostate in a manner that is highly specific to this gland, which is key to their recognized clinical significance in man. They share 80% identity in primary structure and both are proteases, but have distinctly different substrate specificity. Only dogs and some old-world primates such as humans possess functional orthologs of genes coding for hK2, PSA or both; interestingly, man and dog are among the few animal kingdom species known to suffer from prostate cancer. This Review is an evaluation of the literature pertaining to the current risk stratification, diagnostic and prognostic applications and limitations of these kallikreins in prostatic disease. Potential future utility is also touched upon. Discussion of the many other kallikreins (that is, KLK4-KLK15) that have been investigated as candidate biomarkers is beyond the scope of this article.
History of PSA
PSA, initially designated 'gamma-seminoprotein' , was identified in 1966 and characterized in 1971 by Hara et al. 1 These authors anticipated that PSA could be utilized as a marker for seminal fluid in forensic medicine. In 1979, a protein dubbed 'prostate-specific antigen' was purified from prostatic tissue by Wang and associates; this protein was later shown to be identical to gammaseminoprotein and to the P30 antigen. [2] [3] [4] Several subsequent studies recognized the potential utility of PSA as a marker of prostate cancer. [5] [6] [7] The first report on detection of PSA in serum was contributed by Papsidero et al. 6 Normal expression of PSA and hK2
The genes that encode hK2 and PSA, KLK2 and KLK3, respectively, are clustered with other kallikrein genes on chromosome 19. 8 Expression of both KLK2 and KLK3 is induced by androgens. Both proteins are synthesized in a pre-pro precursor form, and activation is a multistep enzymatic process. Low levels of expression of both PSA and hK2 have been detected in several non prostatic tissues, both neoplastic and normal, including the mammary, salivary, pituitary and thyroid glands. 9 Free PSA and complexed PSA Lilja et al. 10 and Stenman et al. 11 independently presented solid evidence in 1991 that the major immunodetected fraction of PSA in serum exists in complex with α1-antichymotrypsin. In addition, Lilja and colleagues identified a distinct PSA-epitope present only on the free, noncomplexed, minor fraction; together, these two fractions accounted for most of the PSA detected in serum. The report by Stenman and co-workers 11 also suggested that the proportion of PSA complexed to α1-antichymotrypsin is higher in men with prostate cancer than in men with benign prostatic hyperplasia (BPH), a finding consistent with that reported by Christensson et al. 12 Conversely, the proportion of free to total PSA was lower in men with prostate cancer than in those with BPH. 12 Numerous investigators have since reported that measuring the ratio of free to total PSA improves discrimination of prostate cancer from BPH. 13, 14 A report by Leinonen et al. 15 indicated that the ratio of complexed to total PSA could be similarly useful; however, as this ratio did not add discriminatory power to the percentage of free PSA (fPSA), further
Competing interests H. Lilja declares that he holds patents for free and complexed PsA (Us5501983 [1996] , eP540573 [1996] , Us5912158 [1999] , Us5939,533 [1999] ) and for hK2 (Us5614,372 [1997] , eP8011164 [1997] ). The other authors declare no competing interests. reviews investigation focused on free and total PSA. During a large multicenter trial, Catalona and co-workers 16 found that prostate biopsies were positive for cancer in 56% of participants with <10% fPSA, but were positive in only 8% of those with >25% fPSA.
Some studies also reported that measuring the percentage of fPSA increases diagnostic accuracy at both low and high total PSA levels. A prospective study revealed that a significant number of clinically relevant tumors are found in men who have PSA levels in the range 1-3 ng/ml and <20% fPSA. 17 Data collected during a large, randomized, population study indicated that low percentages of fPSA in men with PSA levels <3 ng/ml are associated with a 5-10-fold increased risk of a prostate cancer diagnosis. 18 morote et al. 19 demonstrated that determining the percentage of fPSA enhanced the accuracy of prediction of biopsy results in men whose total PSA level was 10-20 ng/ml. A 2005 meta-analysis of 66 studies 20 verified that the percentage of fPSA performs better diagnostically in terms of prostate cancer detection than total PSA does. Data from the Finnish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC) have also been used to evaluate the potential of percentage of fPSA as a risk predictor among men with a PSA level <3 ng/ml. 21 In this study, predictive accuracy declined as total PSA level decreased; with the cutoff set at <15% fPSA, the positive predictive value of percentage of fPSA was 21% for men with a PSA level 2-2.9 ng/ml and 10% for those whose PSA level was less than 2 ng/ml.
As the percentage of fPSA is the only marker that was implemented clinically as a supplementary decisionmaking tool for when to perform a biopsy, the clinical impact of its measurement may be underestimated at times. No current data exist, but the number of negative biopsies performed would probably be even higher if the percentage of fPSA was not being used. -fold higher than that of PSA. PSA that remains unbound in blood (that is, fPSA), therefore, consists of various noncatalytic forms that are incapable of binding these inhibitors; they include precursor and 'nicked' subtypes. Increased levels of various precursor forms have been found in men with prostate cancer, [22] [23] [24] but also in men with prostatitis. 25 A consistent result that has putative clinical value is that the level of PSA nicked between lysine 145 and lysine 146 is elevated in patients with BPH. [26] [27] [28] The clinical potential of assays that measure these PSA subforms is being investigated. Such assays could enhance the predictive accuracy of established markers. The amount of PSA in the blood of men with BPH is linearly associated with the size of their prostate; this correla tion seems to be strongest when prostatic enlargement is restricted to the transition zone and is easily detectable during transrectal ultrasonography (TRuS). 30 Stamey and collaborators reported that BPH tissue produces more PSA per gram than normal prostate tissue, 31 but the accuracy of their data may be questioned. Their precise values are contingent on calibration techniques of that era (the mid-1990s), and the results of this study have not been replicated or verified in an independent cohort. Cross-sectional data from autopsy studies, 32 population-based studies, 33, 34 and clinical trials in men with BPH show that the increase in prostate size with advancing age is matched by a longitudinal rise in PSA level.
Subforms of free PSA

BPH and PSA
Prostatitis and PSA
Prostatitis is a common but ill-defined, benign condition for which clear diagnostic criteria 35 and knowledge of pathological mechanisms 36 are lacking. A four-category classification system for prostatitis was developed under the auspices of the NIH. 37 The lifetime prevalence for symptomatic persistent prostatitis is around 10-15%, and its incidence increases with age. 38 As for BPH and prostate cancer, the incidence of prostatitis is highest among black men and lowest among Asian men. [38] [39] [40] [41] Prostatitis is correlated with a rise in PSA level, irrespective of NIH category, cause or chronicity. [42] [43] [44] [45] [46] The putative mechanism for this PSA increase is that inflamma tion increases vascular permeability, such that PSA seeps into the circulation; 47, 48 however, no correla tion was found between serum PSA level or PSA density and the degree and pattern of inflammation or presence of bacteria. 49 Bozeman et al. 44 retrospectively analyzed data from 95 men who presented with a serum PSA level >4 ng/ml and were subsequently diagnosed with NIH category Iv prostatitis (that is, asymptomatic inflamma tory prostatitis). After 4 weeks of antimicrobial and/or anti-inflammatory reviews treatment, the mean PSA level had dropped by 36%; it decreased to levels below the biopsy cutoff (that is, 4 ng/ml) in 46% of patients. Other investi gations of chronic prostatitis have had similar results. 43 In a prospective study, PSA was measured for 12 months in 54 men with febrile urinary bacterial infection. 50 Total PSA levels decreased slowly postinfection, and remained elevated for up to 6 months; by contrast, the percentage of fPSA decreased rapidly and reached stable levels 1 month after infection. A tempting hypothesis links initia tion of malignant growth to the leakage of enzymes during inflammation and to the increased cell division that occur during healing and reconstruction; however, no correlation between prostatitis and cancer has been shown.
Obesity and PSA
Obesity seems to influence PSA levels. In a prospectively screened cohort of 4,458 men with a median age of 60 years, 51 those who were obese (BmI >30 kg/m 2 ) were 1.8 times more likely to have a low PSA level than were nonobese men (median PSA 1.48 ng/ml versus 1.78 ng/ml, P <0.01). Excess body fat alters the hormonal environment such that increasing BmI correlates with increased estrogen levels and decreased serum androgen concentrations. 52 PSA levels are, in turn, influenced by androgen concentration. 53 In a study by Bañez et al., 54 the PSA levels of men with a BmI >35 kg/m 2 were 10-21% lower than those of men with a normal BmI. Obesity was also associated with large prostate sizes. 54 Given these factors, relating a given PSA level to the risk of prostate cancer is somewhat problematic among obese men. On the basis of data from 28,380 men enrolled in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, Grubb and colleagues 55 proposed that the large plasma volume in men with a high BmI underlay the apparent reduction in PSA concentration in this group. Only further research will determine whether a BmI-based adjustment of PSA thresholds used in clinical practice and for screening trials is required.
A consideration worth noting is that obesity could be due to, as well as cause, hormonal imbalance. medical treatment targeted at obesity-related disease further complicates the research situation. Hamilton and colleagues 56 reported that recent initiation of statin treatment in men was associated with a significant drop in serum PSA level. For men whose PSA was greater than 2.5 ng/ml and whose LDL level dropped by more than 41%, PSA level declined by a median of 17%.
PSA and age
PSA levels tend to increase with age, probably as a function of age-related benign prostatic diseases. In a large Swedish cohort, the median PSA levels for men aged 40-50 years, 51-55 years and 60 years were 0.63 ng/ml, 0.81 ng/ml and 1.1 ng/ml, respectively. [57] [58] [59] In 1993, on the basis of an evaluation of PSA level in 471 nonsymptomatic 'healthy' men aged 40-79 years, Oesterling et al. 60 proposed the following age-related PSA reference ranges: 40-49 years, 0-2.5 ng/ml; 50-59 years, 0-3.5 ng/ml; 60-69 years, 0-4.5 ng/ml; 70-79 years, 0-6.5 ng/ml. The upper limits of these ranges are much higher than those noted in contemporary series, which might be a consequence of the fact that prostate cancer was ruled out by Oesterling and colleagues following digital rectal examina tion and TRuS, rather than biopsy.
PSA and prostate cancer
The increased PSA level associated with prostate cancer is believed to be the result of perturbation of normal tissue anatomy. Prostate cancer is characterized by loss of the basal cell layer, derangement of the basal lamina, diminished epithelial cell polarity, and lack of connection of the glandular acini formed by the prostate epithelial cells. These changes could facilitate leakage of PSA from cancerous cells into intercellular compartments, which are drained by lymphatic vessels into the bloodstream. In advanced cases of prostate cancer these architectural changes can eventually cause a 1,000-fold increase in the amount of PSA released into the blood. Prostatic intraepithelial neoplasia, categorized as either low-grade or high-grade, is characterized by cytologically atypical cells that line architecturally normal ducts. As in prostate cancer, these lesions harbor nuclear and nucleolar abnormalities, 61 but as the basement membrane remains intact 62, 63 serum PSA levels seem to remain unaltered. The first prospective evaluation of the utility of PSA measurement as a screening test for prostate cancer was conducted in 1991 by Catalona et al. 64 They reported that 4 ng/ml was the optimal cutoff value for detecting curable disease while minimizing the number of unneces sary biopsies. Subsequent studies have repeatedly confirmed the association between PSA and prostate cancer, but evidence indicates that the 4 ng/ml threshold is arbitrary; its suitability has been questioned again recently. 65 Smith and colleagues 66 studied a cohort of 10,248 men, and observed that 48% of those whose initial PSA level was <4 ng/ml had concentrations >4 ng/ml within 4 years. Furthermore, 13% of this subgroup were diagnosed with prostate cancer during that period, which indicated that a cutoff lower than 4 ng/ml might hasten diag nosis. A study published 6 years afterwards indicated that a PSA level of between 2.6 ng/ml and 4 ng/ml had 26% positive predictive value for a positive sextant biopsy; 67 tumors from patients with a PSA level in this range were smaller and more likely to be localized to the gland than those removed from patients with a PSA level between 4.1 ng/ml and 10 ng/ml. After publica tion of these two studies, many urologists adjusted their PSA cutoff value for biopsy down to 2.5 ng/ml. The clinical accuracy of this new threshold was confirmed by investigation of the control arm of the Prostate Cancer Prevention Trial, in which 5,112 men underwent annual PSA monitoring for 7 years followed by an end-of-study biopsy. A cutoff of 2.5 ng/ml had a sensitivity for prostate cancer detection of 80%. 68 An important point to note is that the risk of being diagnosed with prostate cancer for a reviews man whose PSA level is below the standard cutoff never reaches zero, which indicates the limited capacity of a single PSA measurement to predict the likelihood of prostate cancer being detected during a biopsy in older men (62-91 years). Furthermore, the accuracy of PSA testing, assessed as area under the receiver operating characteristic curve (AuC) was 0.681 for detection of any prostate cancer and 0.781 for detection of aggressive prostate cancer (Gleason ≥7). 68 This result shows that PSA levels in older men are associated with clinically significant prostate cancer.
PSA dynamics
many studies have focused on how to increase the sensitivity and specificity of PSA as a test for prostate cancer. PSA dynamics and PSA density (see following section) have been proposed as alternatives, with varying degrees of acceptance. Concise summary of these studies is difficult, because the cohorts differ greatly in terms of ethnicity, disease demographics, socioeconomic status and BmI. Some are also affected by selection or verification bias, factors which are seldom taken into consideration.
Carter et al. 69 introduced the concept of PSA velocity-defined as the annual rate of increase in serum PSA value-in 1992. Their initial analysis included 54 participants in the Baltimore Longitudinal Study of Aging. In samples taken 5 years before diagnosis of prostate cancer, they found no difference in PSA levels between participants who would go on to develop this malignancy and those who would develop BPH; PSA velocity, however, was significantly greater in those who were subsequently diagnosed with prostate cancer. The threshold predictive of malignancy, set at 0.75 ng/ml per year, was based on an analysis of samples from 18 men with prostate cancer, 20 with BPH, and 16 with no diagnosis of prostate disease. Fang et al. 70 studied PSA velocity in 89 men from the Baltimore cohort who had PSA levels between 2 ng/ml and 4 ng/ml (21 men with prostate cancer and 68 controls). The probability of being diagnosed with prostate cancer within 10 years was 65% for men with a PSA velocity >0.1 ng/ml per year, compared with 3% for those whose PSA velocity was less than 0.1 ng/ml per year.
A recent analysis of data from the Baltimore Longitudinal Study of Aging focused on 20 patients who died of prostate cancer. At 10-15 years before diagnosis, when the PSA levels of most participants were <4 ng/ml, PSA velocity was associated with risk of dying from prostate cancer. 71 A PSA velocity threshold of >0.35 ng/ml per year identified those at risk of this outcome. A matter of some concern, however, is that these observations were based on data from only 20 men who had died of prostate cancer, versus that of 334 controls. PSA velocity was highly correlated with PSA value (Pearson correlation coefficient, r = 0.70), 71 but the authors did not report whether the predictive accuracy of the combina tion of PSA velocity and PSA value was superior to that of PSA alone. ulmert et al. studied the malmö Preventive Project (mPP) cohort of 4,907 men, of whom 443 were later diagnosed with prostate cancer, and showed that a single PSA measurement up to 15 years beforehand was highly predictive of the subsequent diagnosis. PSA velocity was also strongly associated with a subsequent diagnosis of prostate cancer; however, as the single PSA measurement and PSA velocity were highly correlated (r = 0.93), inclusion of the latter did not enhance the predictive accuracy of the single measurement. Restricting the analysis to those patients with advanced cancer at diagnosis did not alter the results. 58 Other groups who investigated the use of PSA dynamics closer to the time of diagnosis than ulmert and colleagues did reported similar results. 72, 73 In the Prostate Cancer Prevention Trial, PSA velocity did not add any value to the prediction of biopsy outcome beyond that of PSA alone. 72 Similarly, in the Rotterdam arm of the ERSPC, PSA velocity did not improve the prediction of prostate cancer diagnosis in men with PSA levels >4.0 ng/ml. 73 Studies of pretreatment PSA velocity for predicting disease aggressiveness have yielded mixed results. In a retrospective study of PSA velocity measured before radical prostatectomy in 82 men with clinically organconfined prostate cancer, Thiel et al. 74 found no statistically significant relationship between PSA velocity and the extent of cancer. However, in a subsequent study of 1,095 men who underwent radical prostatectomy, D' Amico et al. 75 noted that a PSA velocity >2.0 ng/ml per year during the 12 months before diagnosis was significantly associated with prostate-cancer-specific mortality. A subsequent investigation of 358 patients treated with external radiation therapy yielded similar results. 76 Nevertheless, in neither of these studies did PSA velocity improve the capacity of PSA level alone to predict post-treatment outcome. An analysis of 22 published definitions of PSA dynamics, applied retrospectively for pretreatment assessment of 2,938 patients who underwent radical prostatectomy, showed that both PSA doubling time and PSA velocity were associated with outcome; however, when included in a model that contained the PSA level, no parameter of PSA dynamics improved the predictive capacity of a single pretreatment PSA value. 77 Little-if any-justification may, therefore, exist for including PSA dynamics in models used to predict outcome in patients treated with radical prostatectomy; clinicians were advised to use the most recent PSA value rather than relying on any current definitions of PSA dynamics. 77 Despite PSA dynamics being included in some guidelines, and suggestions that these parameters should form part of the inclusion criteria for clinical trials, the published evidence on the utility of PSA dynamics is insufficient. A recent systematic review found that the majority of articles presenting such evidence did not include PSA dynamics combined with PSA in a prediction model. 78 Only one article showed that PSA velocity could improve the predictive accuracy beyond that of PSA level alone, and this study suffered from verification bias. 79 
reviews
PSA density
Some researchers have proposed that the diagnostic inaccuracy of total PSA is associated with excess PSA production and release by benign nodules in men with BPH. 80, 81 On the basis of this hypothesis, a role for PSA density as a diagnostic tool has been proposed. PSA density is defined as the total PSA level divided by the volume of the entire gland as measured by TRuS. Theoretically, PSA density should be higher in men with a prostatic malignancy than in those with benign conditions, because leakage of PSA into the bloodstream per gram of cancerous tissue is up to ten times that from benign or healthy tissue. 82 Several studies have shown that PSA density is more reliable than total PSA alone as an indication for biopsy, 83, 84 but use of this tool is unfortunately hampered by several factors. Determination of prostate volume varies considerably because TRuS is largely an operator-dependent method. Furthermore, PSA density may yield false-positive results owing to enhancement of PSA leakage in subclinical prostatitis and infarction. Finally, elevated blood concentrations of PSA derived from a tumor may be masked, or diluted, by release of PSA from large volumes of BPH tissue.
Long-term prostate cancer prediction
Several recent reports on the long-term prognostic capacity of kallikreins have been based on data from the mPP, a large, representative, population-based study of cardiovascular risk factors that took place in malmö, Sweden between 1974 and 1992. 85 The study included 22,444 men (participation rate 71.2%), of whom 21,277 were ≤50 years of age at the baseline blood draw. Certain age-groups were invited for re-screening 6 years after baseline (participation rate 72%). By the end of 1999, 498 of the 21,277 participants who were aged less than 50 years at baseline had been diagnosed with prostate cancer. As the rate of PSA screening in Sweden during the study period was very low, the mPP was a 'natural experiment' that tested hypotheses about PSA and prostate cancer.
A nested case-control study of mPP participants aged ≤50 years at baseline showed that a single baseline measurement of total PSA was highly predictive (AuC 0.762) of a subsequent diagnosis of prostate cancer. This utility extended over a considerable period; total PSA measured up to 20 years before diagnosis was similarly predictive. 57 Even a small increase above the populationbased median PSA level (that is, approximately 0.6 ng/ml) was associated with a greatly increased risk of developing prostate cancer; compared with a PSA concentration ≤0.5 ng/ml, a level of 1-2 ng/ml was associated with a sevenfold increase in risk, and a PSA of 2-3 ng/ml with a 19-fold increase in risk. Concentrations of subforms of PSA and hK2 were associated with subsequent diagnosis of prostate cancer, but the predictive accuracy of total PSA alone was not enhanced by adding these parameters. Interestingly, an investigation of the influence of age and delay in diagnosis in a nested case-control study of 1,167 mPP participants aged 60 years at baseline showed that the predictive value of total PSA decreased with increasing age, while the additive predictive power of PSA subforms and hK2 increased. 59 In a recent study, 86 inclusion criteria were narrowed to advanced or metastatic cancers only. The majority (66%) of these cancers occurred in men whose total PSA levels were in the highest quintile. This analysis demonstrated that total PSA was a strong and statistically significant predictor of these advanced cancers (AuC 0.791, P <0.0001) as much as 25 years before diagnosis.
Randomized trials of PSA screening
For the ERSPC, 87 182,000 men aged 50-74 years were recruited from seven European countries. measurement of total PSA level, with a threshold for prostate biopsy of 3 ng/ml, was the principal screening method. In the screening group, 82% of men consented to be tested at least once. On the basis of interim data collected from 162,000 men in the core age-group (55-69 years) during a median follow-up period of 9 years, PSA-based screening reduced the risk of death due to prostate cancer by 20%. Screening was, however, also associated with substantial overdiagnosis; 1,410 men would need to be screened and 48 additional cases of prostate cancer would need to be treated to prevent one death from the disease. 87 Adjustment for noncompliance among the men who were actually screened showed that screening reduced mortality from prostate cancer by 27%.
Interim results from a randomized trial in the uS-the PLCO Cancer Screening Trial-have also been reported. 88 The PLCO study was initiated about the same time as the ERSPC, but detected no reduction in the likelihood of prostate-cancer-related death in association with PSAbased screening. These apparently contradictory outcomes may, in part, be attributed to the smaller sample size in the PLCO trial (approximately 76,600 men), the high rate of PSA testing in the control arm of that trial (52%), the higher rate of prior PSA testing relative to that in the ERSPC, and the lower compliance (41-64% versus 86% in ERSPC) with prostate biopsy among men with an elevated PSA level. 88, 89 In the Swedish arm of the ERSPC, 90 20,000 men aged 50-65 years were recruited from the city of Göteborg; after randomization, half were assigned to the screening group. Since 1995, those with a PSA level <3.0 ng/ml or benign biopsy findings have been invited for biennial testing until they reach the age of 70 years. During 10 years of follow-up, screening increased the likelihood of prostate cancer diagnosis by 1.8-fold. This finding substantiates a commonly cited caveat about PSA-based screening-that it leads to frequent diagnosis of indolent cancers. On the other hand, screening reduced the risk of being diagnosed as having metastatic disease by 49%. 90 The individualized frequency of PSA retesting was addressed by Aus and co-workers, who evaluated the cumulative prostate cancer risk among men with differ ent PSA levels, using data from the Swedish arm of the ERSPC. 90 During a reviews follow-up period of 7.6 years, 539 cases of prostate cancer were diagnosed in the screening arm; no men with a baseline PSA level <0.5 ng/ml were among those so diagnosed. Participants with a PSA concentration between 0.5 ng/ml and 0.99 ng/ml were also at low risk (0.9%) of developing malignancy. 90 The implication of these findings is that the interval between PSA tests could be safely prolonged for men with very low PSA levels. Aus et al. specifically proposed repeating tests every 3 years for men with a PSA concentration ≤1 ng/ml. 90 Several studies based on ERSPC cohorts have shown that PSA levels are strongly predictive of a positive biopsy during initial screening rounds, but not at subsequent screens. Although many clinicians are probably well aware of the influence of prior PSA testing on the predictive value of the PSA test, little research attention has been paid to this important point.
Conclusions
That an increased level of serum PSA could be a function of several benign conditions, as well as an indicator of malignancy, is common clinical knowledge. In men over 50 years of age, benign prostatic conditions are more prevalent than prostate cancer. A single PSA measurement during early middle age-when benign conditions are less prevalent-is a powerful predictive tool. 57 For older men, adding PSA subforms and other kallikreins to the standard laboratory panel could enhance the precision of risk prog nostication. 21, 59 By contrast, PSA dynamics do not improve diag nostic or prognostic precision, and do not aid clinical decision-making. 78 The predictive value of a PSA test decreases dramatically if prior tests have been negative; however, adding PSA subforms and hK2 increases the precision of PSA-based prediction in patients with a history of PSA levels below standard cutoff thresholds for biopsy, and those with an elevated PSA level and a negative biopsy. 91 A major clinical problem is the lack of a predictive method to determine if, and when, a well-differentiated tumor will progress into life-threatening disease. Research to identify new and improved uses of PSA will need to focus on diagnostic methods as well as the clinical significance of prostate cancer.
